Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Alvotech (NASDAQ: ALVO) mun senda út tilkynningu með uppgjöri fyrir fyrri helming ársins 2024 eftir lokun markaða í Bandaríkjunum, fimmtudaginn 15. ágúst nk. Þá mun Alvotech halda kynningarfund fyrir...
-
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first half of the...
-
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe Launch of European-made Uzpruvo in Europe comes immediately upon expiry of exclusivity rights...
-
Fréttatilkynning22. júlí 2024STADA og Alvotech hefja sölu á Uzpruvo, fyrstu líftæknilyfjahliðstæðunni við Stelara í Evrópu Líftæknilyfjahliðstæðan kemur á markað um leið og einkaleyfi fyrir...
-
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
-
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing of its previously...
-
Alvotech (NASDAQ: ALVO) tilkynnti í dag að endurfjármögnun skulda félagsins væri nú lokið. Með því hefur félagið lækkað fjármagnskostnað og lengt lánstíma útistandandi skulda. Að endurfjármögnuninni...
-
REYKJAVIK, Iceland, July 11, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
-
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability...
-
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability...